Opportunity Information: Apply for PAR 09 155
Apply for PAR 09 155
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Translational Research in Pediatric and Obstetric Pharmacology (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Apr 10, 2009 and posted on Apr 10, 2009.
- Applicants must submit their applications by May 19, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: For profit organizations other than small businesses Special district governments State governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Private institutions of higher education Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Translational Research in Pediatric and Obstetric Pharmacology (R01) opportunity (Funding Opportunity Number PAR-09-155) is an NIH grant announcement from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) focused on improving how drugs are studied, developed, and used in children and in pregnant women. The central aim is to support translational research that strengthens evidence on drug safety and effectiveness for these populations, where dosing, metabolism, and clinical responses can differ substantially from typical adult populations and where data gaps have historically been common. Projects supported under this announcement are expected to generate practical, clinically relevant knowledge that can directly inform therapeutic decision-making in pediatrics and obstetrics, or advance new therapeutic options designed specifically with these groups in mind.
Scientifically, the FOA highlights three major priority areas. First, it encourages pharmacologic studies that address differences in drug actions and responses across pediatric developmental stages, between children and adults, and between pregnant and non-pregnant women. This includes work that clarifies how growth and maturation, organ development, hormonal changes, placental physiology, and pregnancy-related shifts in pharmacokinetics and pharmacodynamics can change exposure, efficacy, and toxicity. Second, the FOA supports the development of new drug approaches that specifically target pediatric and obstetric needs, reflecting the reality that many therapies used in these settings are adapted from adult indications rather than designed and validated for children or pregnancy. Third, it emphasizes multidisciplinary, team-based research, particularly collaborations between basic scientists and physician-scientists, to accelerate translation from mechanistic insights to improved real-world therapeutics in obstetrics and pediatrics.
The funding mechanism used is the NIH Research Project Grant (R01), which generally supports substantial, hypothesis-driven research programs that may require multiple years, significant resources, and well-developed preliminary rationale. This FOA is part of a set of parallel announcements with the same scientific scope but different grant mechanisms: PAR-09-154 for the R03 mechanism (typically smaller, shorter projects) and PAR-09-156 for the R21 mechanism (often exploratory or early-stage, higher-risk concepts). Applicants choosing PAR-09-155 are positioning their projects as more mature, comprehensive research efforts appropriate for the R01 scale.
From an administrative and funding standpoint, awards are discretionary and depend on available NIH funds as well as the number and quality of submitted applications; the announcement does not guarantee a specific number of awards. The opportunity is categorized under Health and is tied to CFDA 93.865 (Child Health and Human Development Extramural Research). No cost sharing or matching is required, which is typical for many NIH research grants and can reduce the burden on applicants and institutions.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include for-profit organizations (including small businesses and other for-profits), nonprofit organizations (including those with and without 501(c)(3) status), public and private institutions of higher education, state and local governments (including counties, cities, townships, special districts, and independent school districts), public housing authorities/Indian housing authorities, and Native American tribal governments and organizations (both federally recognized and other than federally recognized). The announcement also explicitly includes a range of special designations and community-focused entities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, regional organizations, foreign organizations (non-U.S. entities), and eligible federal agencies.
Key dates show the FOA was posted and created on April 10, 2009, with an original and current closing date of May 19, 2011, and an archive date of June 19, 2011, meaning it is no longer active for new submissions under that specific announcement number. The full archived announcement was hosted through the NIH grants guide, and the notice provides contact guidance through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Frequently Asked Questions (FAQs)
What is the Translational Research in Pediatric and Obstetric Pharmacology (R01) opportunity?
It is an NIH funding opportunity announcement from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) focused on translational research in pediatric and obstetric pharmacology. The goal is to improve how drugs are studied, developed, and used in children and in pregnant women, with an emphasis on generating clinically useful evidence about safety and effectiveness.
What is the Funding Opportunity Number (FOA number) for this grant?
The Funding Opportunity Number is PAR-09-155.
Which NIH Institute is responsible for this opportunity?
This announcement is from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
What is the central aim of the FOA?
The central aim is to support translational research that strengthens the evidence base for drug safety and effectiveness in children and pregnant women, where dosing, metabolism, and clinical responses can differ substantially from typical adult populations and where data gaps have historically been common.
What types of outcomes or impacts are projects expected to deliver?
Projects are expected to generate practical, clinically relevant knowledge that can directly inform therapeutic decision-making in pediatrics and obstetrics, or advance new therapeutic options designed specifically for children and/or pregnant women.
Why does NIH emphasize pediatrics and pregnancy for drug research in this FOA?
The FOA highlights that children and pregnant women can have substantially different dosing needs, metabolism, and clinical responses compared with typical adult populations. It also notes that these populations have historically had common data gaps related to drug safety and effectiveness.
What are the main scientific priority areas in this FOA?
The FOA highlights three major priority areas: (1) pharmacologic studies addressing differences in drug actions and responses across pediatric developmental stages, between children and adults, and between pregnant and non-pregnant women; (2) development of new drug approaches that specifically target pediatric and obstetric needs; and (3) multidisciplinary, team-based research, especially collaborations between basic scientists and physician-scientists to speed translation into improved therapeutics.
What kinds of differences in drug response does the FOA specifically call out?
The FOA points to factors such as growth and maturation, organ development, hormonal changes, placental physiology, and pregnancy-related shifts in pharmacokinetics and pharmacodynamics that can alter exposure, efficacy, and toxicity.
Does the FOA encourage comparisons across groups (children vs adults, pregnant vs non-pregnant)?
Yes. It encourages pharmacologic studies that address differences in drug actions and responses across pediatric developmental stages, between children and adults, and between pregnant and non-pregnant women.
Is this FOA limited to studying existing drugs, or can it support new therapeutic approaches?
It supports both. In addition to studies clarifying drug actions and responses, it also supports the development of new drug approaches that are designed to meet pediatric and obstetric needs, recognizing that many therapies in these settings are adapted from adult indications rather than created and validated for children or pregnancy.
What kind of research approach is emphasized (basic, clinical, or translational)?
The FOA is centered on translational research and emphasizes moving from mechanistic insights toward practical improvements in real-world therapeutics for obstetrics and pediatrics. It explicitly encourages multidisciplinary collaboration to accelerate translation.
What funding mechanism does PAR-09-155 use?
PAR-09-155 uses the NIH Research Project Grant (R01) mechanism.
What does it mean that this is an R01 opportunity?
An R01 generally supports substantial, hypothesis-driven research programs that may require multiple years, significant resources, and a well-developed preliminary rationale. Under this FOA, choosing the R01 mechanism positions the project as a more mature and comprehensive research effort suitable for R01 scale.
Are there related opportunities with the same scientific scope but different mechanisms?
Yes. The FOA is part of a set of parallel announcements with the same scientific scope: PAR-09-154 for the R03 mechanism and PAR-09-156 for the R21 mechanism.
How do the parallel mechanisms differ, based on the information provided?
According to the description: R03 is typically used for smaller, shorter projects; R21 is often used for exploratory or early-stage, higher-risk concepts; and R01 (PAR-09-155) is for more mature, comprehensive projects.
Is a specific number of awards guaranteed?
No. Awards are discretionary and depend on available NIH funds as well as the number and quality of applications submitted. The announcement does not guarantee a specific number of awards.
Is cost sharing or matching required for this grant?
No. The opportunity states that no cost sharing or matching is required.
What is the program area or category for this opportunity?
The opportunity is categorized under Health.
What CFDA number is associated with this opportunity?
The opportunity is tied to CFDA 93.865 (Child Health and Human Development Extramural Research).
Who is eligible to apply?
Eligibility is broad and includes domestic and non-domestic organizations. Eligible applicants include for-profit organizations (including small businesses and other for-profits), nonprofit organizations (including those with and without 501(c)(3) status), public and private institutions of higher education, and various government and community-based entities.
Can for-profit organizations apply?
Yes. The FOA includes for-profit organizations, including small businesses and other for-profits, as eligible applicants.
Can nonprofit organizations apply even if they do not have 501(c)(3) status?
Yes. The FOA includes nonprofit organizations both with and without 501(c)(3) status.
Are universities and colleges eligible applicants?
Yes. Public and private institutions of higher education are explicitly listed as eligible.
Are state and local government entities eligible?
Yes. State and local governments are eligible, including counties, cities, townships, special districts, and independent school districts.
Are tribal governments and tribal organizations eligible?
Yes. The FOA includes Native American tribal governments and organizations, both federally recognized and other than federally recognized.
Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed as eligible applicants.
Does the FOA include special designations such as HBCUs and Hispanic-serving institutions?
Yes. The announcement explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are explicitly included.
Are U.S. territories or possessions included in eligibility?
Yes. The FOA explicitly includes U.S. territories or possessions.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA includes foreign organizations (non-U.S. entities) as eligible applicants.
Are federal agencies eligible to apply?
Yes. The FOA states that eligible federal agencies are included.
When was this FOA posted and created?
The FOA was posted and created on April 10, 2009.
What were the closing dates for this opportunity?
The original and current closing date listed is May 19, 2011.
Is this funding opportunity still active?
No. The FOA has an archive date of June 19, 2011, indicating it is no longer active for new submissions under PAR-09-155.
Where was the full announcement hosted?
The full archived announcement was hosted through the NIH grants guide.
Who is listed as a contact for access or linking issues?
The notice provides contact guidance through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Translational Research in Pediatric and Obstetric Pharmacology (R21)
Previous opportunity: Translational Research in Pediatric and Obstetric Pharmacology (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 09 155
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 09 155) also looked into and applied for these:
| Funding Opportunity |
|---|
| Translational Research in Pediatric and Obstetric Pharmacology (R21) Apply for PAR 09 156 Funding Number: PAR 09 156 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $275,000 |
| Womens Reproductive Health Research (WRHR) Career Development Program (K12) Apply for RFA HD 09 026 Funding Number: RFA HD 09 026 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $440,000 |
| Considerations For The Safe and Effective Use of Iron Interventions In Context of Malaria and Its Co morbidities (U01) Apply for RFA HD 09 029 Funding Number: RFA HD 09 029 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Factors Affecting Cognitive Function in Adults with Down Syndrome (R01) Apply for RFA HD 09 028 Funding Number: RFA HD 09 028 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $500,000 |
| Noninvasive Assays of Human Oocytes and Preimplantation Embryos (STTR R41) Apply for RFA HD 09 024 Funding Number: RFA HD 09 024 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $100,000 |
| Noninvasive Assays of Human Oocytes and Preimplantation Embryos (SBIR R43) Apply for RFA HD 09 025 Funding Number: RFA HD 09 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $100,000 |
| Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54) Apply for RFA HD 09 027 Funding Number: RFA HD 09 027 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,000,000 |
| Safe and Effective Instruments and Devices for use in the Neonatal Intensive Care Units (STTR R41) Apply for RFA HD 09 018 Funding Number: RFA HD 09 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Advanced Tools and Technologies for Cerebrospinal Fluid Shunts STTR (R41/R42) Apply for PA 09 205 Funding Number: PA 09 205 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Advanced Tools and Technologies for Cerebrospinal Fluid Shunts SBIR (R43/R44) Apply for PA 09 206 Funding Number: PA 09 206 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Medical Rehabilitation Research Resource (R24) Apply for RFA HD 09 013 Funding Number: RFA HD 09 013 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fertility Preservation Research Advancing Beyond Technology (R01) Apply for RFA HD 09 009 Funding Number: RFA HD 09 009 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $500,000 |
| Limited Competition Addressing Health Disparities in Maternal and Child Health through Community Based Participatory Research (R03) Apply for RFA HD 09 010 Funding Number: RFA HD 09 010 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $75,000 |
| Genetic and Genomic Analysis of Xenopus (R03) Apply for PAR 09 242 Funding Number: PAR 09 242 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Cooperative Research Partnerships to Promote Workforce Diversity in the Reproductive Sciences (U01) Apply for RFA HD 09 008 Funding Number: RFA HD 09 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $400,000 |
| Population Research Infrastructure Program (PRIP) FY10 (R24) Apply for RFA HD 09 004 Funding Number: RFA HD 09 004 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
| The Role of Human Animal Interaction in Child Health and Development (R03) Apply for RFA HD 09 030 Funding Number: RFA HD 09 030 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Epigenetic Processes in Development (R21) Apply for RFA HD 09 033 Funding Number: RFA HD 09 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Specialized Cooperative Centers Program in Reproduction and Infertility Research (U54) Apply for RFA HD 09 032 Funding Number: RFA HD 09 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Intellectual and Developmental Disabilities Research Centers 2010 (P30) Apply for RFA HD 09 012 Funding Number: RFA HD 09 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 09 155", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.